Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever
Open accessAbstract
BACKGROUND: Patients with neutropenia and persistent fever are often treated empirically with amphotericin B or liposomal amphotericin B to prevent invasive fungal infections. Antifungal triazoles offer a potentially safer and effective alternative. METHODS: In a randomized, international, multicenter trial, we compared voriconazole, a new second-generation triazole, with liposomal amphotericin B for empirical antifungal therapy. RESULTS: A total of 837 patients (415 assigned to voriconazole and 422 to liposomal amphotericin B) were evaluated for success of treatment. The overall success rates were 26.0 percent with voriconazole and 30.6 percent with liposomal amphotericin B (95 percent confidence interval for the difference, -10.6 to 1.6 percentage points); these rates were independent of the administration of antifungal prophylaxis or the use of colony-stimulating factors. There were fewer documented breakthrough fungal infections in patients treated with voriconazole than in those treated with liposomal amphotericin B (8 [1.9 percent] vs. 21 [5.0 percent], P=0.02). The voriconazole group had fewer cases of severe infusion-related reactions (P<0.01) and of nephrotoxicity (P<0.001). The incidence of hepatotoxicity was similar in the two groups. Patients receiving voriconazole had more episodes of transient visual changes than those receiving liposomal amphotericin B (22 percent vs. 1 percent, P<0.001) and more hallucinations (4.3 percent vs. 0.5 percent, P<0.001). Parenteral voriconazole was changed to the oral formulation in 22 percent of the voriconazole group, with a reduction in the mean duration of hospitalization by one day in all patients (P=0.17) but by two days in patients at high risk (P=0.03). CONCLUSIONS: Voriconazole is a suitable alternative to amphotericin B preparations for empirical antifungal therapy in patients with neutropenia and persistent fever.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Voriconazole has been shown to be active in high-risk patients for prevention of breakthrough fungal infections.
“Voriconazole has been shown to be active in high-risk patients (e.g., allogeneic bone marrow transplant recipients and individuals with relapsed leukemia) for prevention of breakthrough fungal infections [147].”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [147]
Voriconazole is superior to liposomal amphotericin B in the prevention of breakthrough fungal infections in high-risk patients.
“voriconazole has been shown to be superior to liposomal amphotericin B in the prevention of breakthrough fungal infections in high-risk patients (A-I).”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [155]
Voriconazole is superior to liposomal amphotericin B in the prevention of breakthrough fungal infections in high-risk patients.
“voriconazole has been shown to be superior to liposomal amphotericin B in the prevention of breakthrough fungal infections in high-risk patients (A-I).”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [147]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205 · see citing works
Self-citationCurrent and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137 · see citing works
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039 · see citing works
Self-citationPractice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927 · see citing works
Self-citationPizzo, P. A., Robichaud, K. J., Gill, F. A., & Witebsky, F. G. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90594-0 · Cited by 859 · see citing works
Management of Fever in Patients with Cancer and Treatment-Induced Neutropenia
Wood, A. J. J., & Pizzo, P. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305063281808 · Cited by 847 · see citing works
Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791 · see citing works
Self-citation1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever
Hughes, W. T., Armstrong, D., Bodey, G. P., Brown, A. E., Edwards, J. E., Feld, R. D., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., & Young, L. S. (1997) · Clinical Infectious Diseases · doi:10.1086/513764 · Cited by 668 · see citing works
Prentice, H. G., Hann, I. M., Herbrecht, R., Aoun, M., Kvaløy, S., Catovsky, D., Pinkerton, R., Schey, S., Jacobs, F., Oakhill, A., et al. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2473063.x · Cited by 437 · see citing works
Empiric antifungal therapy in febrile granulocytopenic patients
Meunier, F. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90441-5 · Cited by 407 · see citing works
Lipid Formulations of Amphotericin B: Clinical Efficacy and Toxicities
Wong‐Beringer, A., Jacobs, R. A., & Guglielmo, B. J. (1998) · Clinical Infectious Diseases · doi:10.1086/514704 · Cited by 398 · see citing works
Espinel-Ingroff, A. V. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.1.198-202.1998 · Cited by 363 · see citing works
Boogaerts, M., Winston, D. J., Bow, E. J., Garber, G., Reboli, A. C., Schwarer, A. P., Novitzky, N., Boehme, A., Chwetzoff, E., De Beule, K., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00010 · Cited by 321 · see citing works
Self-citationEmerging Fungal Pathogens in Immunocompromised Patients: Classification, Diagnosis, and Management
Vartivarian, S. E., Anaissie, E. J., & Bodey, G. P. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.supplement_2.s487 · Cited by 241 · see citing works
Self-citationRibaud, P., Chastang, C., Latgé, J., Baffroy‐Lafitte, L., Parquet, N., Espéton, A. D. H., Sélimi, F., Rocha, V., Derouin, F., Socié, G., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/515116 · Cited by 233 · see citing works
Espinel-Ingroff, A., Bartlett, M., Bowden, R., Chin, N. X., Cooper, C., Fothergill, A., McGinnis, M. R., Menezes, P., Messer, S. A., Nelson, P. W., et al. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.1.139-143.1997 · Cited by 228 · see citing works
Self-citationWinston, D. J., Hathorn, J. W., Schuster, M. G., Schiller, G. J., & Territo, M. C. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00457-x · Cited by 189 · see citing works
Walsh, T. J., Yeldandi, V. V., McEvoy, M., Gonzalez, C. E., Chanock, S. J., Freifeld, A. G., Seibel, N., Whitcomb, P. O., Jarosinski, P. F., Boswell, G. W., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2391 · Cited by 189 · see citing works
Self-citationGuiot, H. F. L., Fibbe, W. E., & Wout, J. W. V. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.4.525 · Cited by 180 · see citing works
Viscoli, C., Castagnola, E., Van Lint, M. T., Moroni, C., Garaventa, A., Rossi, M. R., Fanci, R., Menichetti, F., Caselli, D., Giacchino, M., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00619-2 · Cited by 122 · see citing works
Infections with Aspergillus Species
Andriole, V. T. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.supplement_2.s481 · Cited by 110 · see citing works
Malik, I. A., Moid, I., Aziz, Z., Khan, S., & Suleman, M. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00326-x · Cited by 106 · see citing works
New investigational antifungal agents for treating invasive fungal infections
Hossain, M. A., & Ghannoum, M. A. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.8.1797 · Cited by 95 · see citing works
In vitro activity of voriconazole against selected fungi
McGinnis, M. R., Pasarell, L., Sutton, D. A., et al. (1998) · Medical Mycology · doi:10.1046/j.1365-280x.1998.00153.x · Cited by 94 · see citing works
A rapid HPLC assay for voriconazole in human plasma
Gage, R., & Stopher, D. A. (1998) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(98)00004-1 · Cited by 94 · see citing works
In vitroactivity of voriconazole against selected fungi
McGinnis, M. R., Pasarell, L., Sutton, D. A., et al. (1998) · Medical Mycology · doi:10.1080/02681219880000361 · Cited by 64 · see citing works
Johnson, M. D., Drew, R. H., & Perfect, J. R. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03934.x · Cited by 53 · see citing works
Self-citationResponse to Empiric Amphotericin B During Antileukemic Therapy-Induced Granulocytopenia
Karp, J. E., Merz, W. G., & Charache, P. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.4.592 · Cited by 50 · see citing works
New Concepts in the Pulmonary Disposition of Antibiotics
Bergogne-Bérézin, E. (1995) · Pulmonary Pharmacology · doi:10.1006/pulp.1995.1009 · Cited by 44 · see citing works
Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia
Arning, M., Heer‐Sonderhoff, A. H., Wehmeier, A., & Schneider, W. (1995) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf02112616 · Cited by 34 · see citing works
Prognostic Factors of Invasive Pulmonary Aspergillosis in Leukemic Patients
Ribrag, V., Dreyfus, F., Alain Venot, A., et al. (1993) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199309148554 · Cited by 28 · see citing works
Castleman's disease in poems syndrome with elevated interleukin‐6
Mandler, R., Kerrigan, D., Smart, J., Kuis, W., Villiger, P., & Lotz, M. (1992) · Cancer · doi:10.1002/1097-0142(19920601)69:11 · Cited by 12 · see citing works
Flagged first, then by citations
Research works printed but not linked: 5
- Pannuti C, Gingrich R, Pfaller MA, Kao C, Wenzel RP. Nosocomial pneumonia in patients having bone marrow transplant: attributable mor- tality and risk factors. Cancer 1992;69:2653-62.
- Walsh TJ, Lutsar TI, Ghahramani P, et al. Efficacy of safety of vori- conazole (VORI) and the treatment of invasive fungal infection in children. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17-20, 2000. abstract.
- Ascioglu S, Rex JH, de Pauw B, et al. Analysis of definitions used in clinical research on invasive fungal infections: consensus proposal for new, standardized definitions. Clin Infect Dis (in press).
- Herbrecht R , Denning DW, Patterson TF, et al. Open, randomized comparison of voriconazole (VRC) and amphotericin B (AmB) followed by other licensed antifungal therapy of invasive aspergillosis (IA). In: Pro- gram and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16-19, 2001.
- Washing- ton, D.C.: American Society for Microbiology (in press). abstract.
Cited by
Sorted by citations
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917 · see citing works
Self-citationPappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200 · see citing works
Self-citationFreifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463 · see citing works
Self-citationVoriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304 · see citing works
Self-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · see citing works
Self-citationPatterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926 · see citing works
Self-citationUllmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556 · see citing works
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · see citing works
Self-citationPascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O. (2008) · Clinical Infectious Diseases · doi:10.1086/524669 · Cited by 887 · see citing works
Stone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016) · Drugs · doi:10.1007/s40265-016-0538-7 · Cited by 537 · see citing works
WALSH, T. J., LUTSAR, I., DRISCOLL, T., DUPONT, B., RODEN, M., GHAHRAMANI, P., HODGES, M., GROLL, A. H., & PERFECT, J. R. (2002) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200203000-00015 · Cited by 431 · see citing works
Self-citationInvasive Aspergillosis: Epidemiology, Diagnosis and Management in Immunocompromised Patients
Maschmeyer, G., Haas, A., & Cornely, O. A. (2007) · Drugs · doi:10.2165/00003495-200767110-00004 · Cited by 366 · see citing works
Ullmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12041 · Cited by 334 · see citing works
Therapy for fungal diseases: opportunities and priorities
Denning, D. W., & Hope, W. W. (2010) · Trends in Microbiology · doi:10.1016/j.tim.2010.02.004 · Cited by 314 · see citing works
Antifungal drug resistance to azoles and polyenes
Canuto, M. M., & Rodero, F. G. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00371-7 · Cited by 310 · see citing works
Pfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A., Odds, F. C., Rinaldi, M. G., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.819-826.2006 · Cited by 258 · see citing works
Self-citationOstrosky-Zeichner, L., Kontoyiannis, D., Raffalli, J., Mullane, K. M., Vazquez, J., Anaissie, E. J., Lipton, J., Jacobs, P., Rensburg, J. H. J., Rex, J. H., et al. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0024-8 · Cited by 189 · see citing works
Self-citationSegal, B. H., Almyroudis, N. G., Battiwalla, M., Herbrecht, R., Perfect, J. R., Walsh, T. J., & Wingard, J. R. (2007) · Clinical Infectious Diseases · doi:10.1086/510677 · Cited by 168 · see citing works
Self-citationClancy, C. J., Pappas, P. G., Vazquez, J., Judson, M. A., Kontoyiannis, D. P., Thompson, G. R., Garey, K. W., Reboli, A., Greenberg, R. N., Apewokin, S., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1095 · Cited by 165 · see citing works
Self-citationTriazole resistance surveillance in Aspergillus fumigatus
Resendiz Sharpe, A., Lagrou, K., Meis, J. F., Chowdhary, A., Lockhart, S. R., Verweij, P. E., & on behalf of the ISHAM/ECMM Aspergillus Resistance Surveillance working group (2018) · Medical Mycology · doi:10.1093/mmy/myx144 · Cited by 150 · see citing works
Lionakis, M. S., Lewis, R. E., & Kontoyiannis, D. P. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy473 · Cited by 145 · see citing works
Pfaller, M. A., Andes, D., Arendrup, M. C., Diekema, D. J., Espinel-Ingroff, A., Alexander, B. D., Brown, S. D., Chaturvedi, V., Fowler, C. L., Ghannoum, M. A., et al. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.03.002 · Cited by 130 · see citing works
Self-citationDeterminants of Candidemia and Candidemia-Related Death in Cardiothoracic ICU Patients
Michalopoulos, A. S., Geroulanos, S., & Mentzelopoulos, S. D. (2003) · Chest · doi:10.1378/chest.124.6.2244 · Cited by 121 · see citing works
Clinical efficacy of new antifungal agents
Kauffman, C. A. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.08.001 · Cited by 64 · see citing works
Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options
Ashley, E. D., Drew, R., Johnson, M., Danna, R., Dabrowski, D., Walker, V., Prasad, M., Alexander, B., Papadopoulos, G., & Perfect, J. (2012) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2012.01124 · Cited by 62 · see citing works
Self-citationVoriconazole versus Liposomal Amphotericin B in Patients with Neutropenia and Persistent Fever
Powers, J. H., Dixon, C. A., & Goldberger, M. J. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460414 · Cited by 61 · see citing works
EUCAST technical note on Amphotericin B
Lass-Flörl, C., Arendrup, M. C., Rodriguez-Tudela, J.-L., Cuenca-Estrella, M., Donnelly, P., & Hope, W. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03644.x · Cited by 49 · see citing works
Invasive Aspergillosis in Hematological Patients
Kimura, S.-I. (2016) · Medical Mycology Journal · doi:10.3314/mmj.57.j77 · Cited by 14 · see citing works
Decisions about Voriconazole versus Liposomal Amphotericin B
(2002) · New England Journal of Medicine · doi:10.1056/nejm200205093461915 · Cited by 14 · see citing works
- Authors
- Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., Schuster, M., Reboli, A., Wingard, J., Arndt, C., Reinhardt, J., Hadley, S., Finberg, R., Laverdière, M., Perfect, J., Garber, G., Fioritoni, G., Anaissie, E., & Lee, J.
- Affiliations
- National Institutes of Health (US)
- University of Alabama at Birmingham (US)
- University of California, Los Angeles (US)
- University Hospitals of Cleveland (US)
- University of Utah (US)
- New York Medical College (US)
- Virginia Commonwealth University Medical Center (US)
- Loyola University Medical Center (US)
- University of Kentucky (US)
- University of Virginia (US)
- National Institute of Allergy and Infectious Diseases (US)
- Mayo Clinic (US)
- Beth Israel Deaconess Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-01-24
- Volume
- 346
- Issue
- 4
- Pages
- 225-234
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2029714817
- Cited by
- 979
- References
- 32
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 8 · 2023: 5 · 2022: 14 · 2021: 21 · 2020: 12 · 2019: 21 · 2018: 20 · 2017: 20 · 2016: 20 · 2015: 28 · 2014: 37 · 2013: 38 · 2012: 42
- FWCI
- 55.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- VCU Scholars Compass (Virginia Commonwealth University) (submittedVersion)
- Funders
- Pfizer
- National Institutes of Health (n01ai065296-009)
- National Institute of Allergy and Infectious Diseases (N01AI65296)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Keywords
- voriconazole, liposomal amphotericin B, empirical antifungal therapy, neutropenia, persistent fever, invasive fungal infections, antifungal prophylaxis, breakthrough fungal infection, infusion reactions, nephrotoxicity, hepatotoxicity, visual disturbances, hallucinations, length of hospital stay
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Amphotericin B, Anti-Bacterial Agents, Antifungal Agents, Child, Chronic Disease, Female, Fever, Humans, Infusions, Intravenous, Male, Middle Aged, Mycoses, Neoplasms, Neutropenia, Prospective Studies, Pyrimidines, Triazoles, Chemical and Drug Induced Liver Injury, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
